Related references
Note: Only part of the references are listed.The introduction of immunosuppressor (TDO inhibitor) significantly improved the efficacy of irinotecan in treating hepatocellular carcinoma
Qingqing Liu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
GBP1 Facilitates Indoleamine 2,3-Dioxygenase Extracellular Secretion to Promote the Malignant Progression of Lung Cancer
Yinnan Meng et al.
FRONTIERS IN IMMUNOLOGY (2021)
Discovery and Preclinical Evaluation of BMS-986242, a Potent, Selective Inhibitor of Indoleamine-2,3-dioxygenase 1
Emily C. Cherney et al.
ACS MEDICINAL CHEMISTRY LETTERS (2021)
Targeting Indoleamine 2,3-Dioxygenase in Cancer Models Using the Novel Small Molecule Inhibitor NTRC 3883-0
Yvonne Grobben et al.
FRONTIERS IN IMMUNOLOGY (2021)
Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours
Takahiro Ebata et al.
INVESTIGATIONAL NEW DRUGS (2020)
Downregulation of kynureninase restrains cutaneous squamous cell carcinoma proliferation and represses the PI3K/AKT pathway
C. Ci et al.
CLINICAL AND EXPERIMENTAL DERMATOLOGY (2020)
Targeting tryptophan catabolic kynurenine pathway enhances antitumor immunity and cytotoxicity in multiple myeloma
Arghya Ray et al.
LEUKEMIA (2020)
A highly efficient modality to block the degradation of tryptophan for cancer immunotherapy: locked nucleic acid-modified antisense oligonucleotides to inhibit human indoleamine 2,3-dioxygenase 1/tryptophan 2,3-dioxygenase expression
Richard Klar et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
Immunometabolic Network Interactions of the Kynurenine Pathway in Cutaneous Malignant Melanoma
Soudabeh Rad Pour et al.
FRONTIERS IN ONCOLOGY (2020)
Inhibition of Tryptophan-Dioxygenase Activity Increases the Antitumor Efficacy of Immune Checkpoint Inhibitors
Florence Schramme et al.
CANCER IMMUNOLOGY RESEARCH (2020)
IDO Targeting in Sarcoma: Biological and Clinical Implications
Imane Nafia et al.
FRONTIERS IN IMMUNOLOGY (2020)
Activation of the Kynurenine Pathway in Human Malignancies Can Be Suppressed by the Cyclin-Dependent Kinase Inhibitor Dinaciclib
Christin Riess et al.
FRONTIERS IN IMMUNOLOGY (2020)
A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant glioma
David A. Reardon et al.
INVESTIGATIONAL NEW DRUGS (2020)
Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine
Luis Felipe Campesato et al.
NATURE COMMUNICATIONS (2020)
Indoleamine 2,3-dioxygenase in melanoma progression and BRAF inhibitor resistance
Silvana Sandri et al.
PHARMACOLOGICAL RESEARCH (2020)
1-MT inhibits the invasion of CBP-resistant ovarian cancer cells via down-regulating IDO expression and re-activating immune cells function
Huihan Ma et al.
BMC PHARMACOLOGY & TOXICOLOGY (2020)
Differential kynurenine pathway metabolism in highly metastatic aggressive breast cancer subtypes: beyond IDO1-induced immunosuppression
Benjamin Heng et al.
BREAST CANCER RESEARCH (2020)
Both IDO1 and TDO contribute to the malignancy of gliomas via the Kyn-AhR-AQP4 signaling pathway
Lisha Du et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
4,6-Substituted-1 H-Indazoles as potent IDO1/TDO dual inhibitors
Lingling Yang et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2019)
IDO1 and Kynurenine Pathway Metabolites Activate PI3K-Akt Signaling in the Neoplastic Colon Epithelium to Promote Cancer Cell Proliferation and Inhibit Apoptosis
Kumar S. Bishnupuri et al.
CANCER RESEARCH (2019)
Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors
Kyung Hae Jung et al.
CLINICAL CANCER RESEARCH (2019)
IDO1 Inhibition Overcomes Radiation-Induced Rebound Immune Suppression by Reducing Numbers of IDO1-Expressing Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Ailin Li et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)
IDO1 inhibition potentiates vaccine-induced immunity against pancreatic adenocarcinoma
Alex B. Blair et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Target exposure and pharmacodynamics study of the indoleamine 2,3-dioxygenase-1 (IDO-1) inhibitor epacadostat in the CT26 mouse tumor model
Lauranne Poncelet et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2019)
Co-expression of IDO1 and PD-L1 in lung squamous cell carcinoma: Potential targets of novel combination therapy
Kazuki Takada et al.
LUNG CANCER (2019)
The Yin' and the Yang' of the kynurenine pathway: excitotoxicity and neuroprotection imbalance in stress-induced disorders
Pascal Barone
BEHAVIOURAL PHARMACOLOGY (2019)
Investigation of the absolute bioavailability and human mass balance of navoximod, a novel IDO1 inhibitor
Shuguang Ma et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Design and Synthesis of Indoleamine 2,3-Dioxygenase 1 Inhibitors and Evaluation of Their Use as Anti-Tumor Agents
Hui Wen et al.
MOLECULES (2019)
Limitations and Off-Target Effects of Tryptophan-Related IDO Inhibitors in Cancer Treatment
Juliane Guenther et al.
FRONTIERS IN IMMUNOLOGY (2019)
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
Georgina Long et al.
LANCET ONCOLOGY (2019)
Carboxyamidotriazole combined with IDO1-Kyn-AhR pathway inhibitors profoundly enhances cancer immunotherapy
Jing Shi et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Carbidopa Alters Tryptophan Metabolism in Breast Cancer and Melanoma Cells Leading to the Formation of Indole-3-Acetonitrile, a Pro-Proliferative Metabolite
Diana Duarte et al.
BIOMOLECULES (2019)
Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan-Kynurenine-Aryl Hydrocarbon Axis
Brian W. Labadie et al.
CLINICAL CANCER RESEARCH (2019)
A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes
Rami S. Komrokji et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)
Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation
Xi Xu et al.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2019)
Targeting indoleamine-2,3-dioxygenase in cancer: Scientific rationale and clinical evidence
Biagio Ricciuti et al.
PHARMACOLOGY & THERAPEUTICS (2019)
Recent advances in the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors
Xiu-Xiu Wang et al.
MEDCHEMCOMM (2019)
The extracts of Astragalus membranaceus enhance chemosensitivity and reduce tumor indoleamine 2, 3-dioxygenase expression
Naphichaya Phacharapiyangkul et al.
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES (2019)
Role of IDO and TDO in Cancers and Related Diseases and the Therapeutic Implications
Zixiang Ye et al.
JOURNAL OF CANCER (2019)
Indoleamine-2,3-Dioxygenase in Non-Small Cell Lung Cancer A Targetable Mechanism of Immune Resistance Frequently Coexpressed With PD-L1
Ashley Volaric et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2018)
Indoleamine 2,3-Dioxygenase (IDO) Inhibition as a Strategy to Augment Cancer Immunotherapy
Sarah Yentz et al.
BIODRUGS (2018)
LW106, a novel indoleamine 2,3-dioxygenase 1 inhibitor, suppresses tumour progression by limiting stroma-immune crosstalk and cancer stem cell enrichment in tumour micro-environment
Rong Fu et al.
BRITISH JOURNAL OF PHARMACOLOGY (2018)
Indoleamine 2,3-dioxygenase 1 inhibition targets anti-PD1-resistant lung tumors by blocking myeloid-derived suppressor cells
Ailin Li et al.
CANCER LETTERS (2018)
Discovery of a polysaccharide from the fruiting bodies of Lepista sordida as potent inhibitors of indoleamine 2, 3-dioxygenase (IDO) in HepG2 cells via blocking of STAT1-mediated JAK-PKC-δ signaling pathways
Qiang Luo et al.
CARBOHYDRATE POLYMERS (2018)
Regulation of the Immune Response by the Aryl Hydrocarbon Receptor
Cristina Gutierrez-Vazquez et al.
IMMUNITY (2018)
1-L-MT, an IDO inhibitor, prevented colitis-associated cancer by inducing CDC20 inhibition-mediated mitotic death of colon cancer cells
Xiuting Liu et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
The enhanced antitumour response of pimozide combined with the IDO inhibitor L-MT in melanoma
Huijie Jia et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2018)
PD-1 inhibition in sarcoma still needs investigation
Maud Toulmonde et al.
LANCET ONCOLOGY (2018)
Indoleamine 2, 3-dioxygenase regulation of immune response
Hao Wu et al.
MOLECULAR MEDICINE REPORTS (2018)
Kynurenine promotes the goblet cell differentiation of HT-29 colon carcinoma cells by modulating Wnt, Notch and AhR signals
Joo-Hung Park et al.
ONCOLOGY REPORTS (2018)
Modulating Tumor Immunology by Inhibiting Indoleamine 2,3-Dioxygenase (IDO): Recent Developments and First Clinical Experiences
Diwakar Davar et al.
TARGETED ONCOLOGY (2018)
Targeting the IDO1/TDO2-KYN-AhR Pathway for Cancer Immunotherapy - Challenges and Opportunities
Jae Eun Cheong et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2018)
Aminoisoxazoles as Potent Inhibitors of Tryptophan 2,3-Dioxygenase 2 (TDO2)
Zhonghua Pei et al.
ACS MEDICINAL CHEMISTRY LETTERS (2018)
A Longitudinal Analysis of IDO and PDL1 Expression during Immune- or Targeted Therapy in Advanced Melanoma
Lukas Krahenbuhl et al.
NEOPLASIA (2018)
Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas A Phase 2 Clinical Trial
Maud Toulmonde et al.
JAMA ONCOLOGY (2018)
Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study.
Georgina V. Long et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Targeting the IDO1 pathway in cancer: from bench to bedside
Ming Liu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Characterization of the Selective lndoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
Bruno Gomes et al.
MOLECULAR CANCER THERAPEUTICS (2018)
The Combined Use of Melatonin and an Indoleamine 2,3-Dioxygenase-1 Inhibitor Enhances Vaccine-Induced Protective Cellular Immunity to HPV16-Associated Tumors
Ana C. R. Moreno et al.
FRONTIERS IN IMMUNOLOGY (2018)
Feiji Recipe inhibits the growth of lung cancer by modulating T-cell immunity through indoleamine-2,3-dioxygenase pathway in an orthotopic implantation model
Bin Luo et al.
JOURNAL OF INTEGRATIVE MEDICINE-JIM (2018)
Bortezomib Relieves Immune Tolerance in Nasopharyngeal Carcinoma via STAT1 Suppression and Indoleamine 2,3-Dioxygenase Downregulation
Guan-Min Jiang et al.
CANCER IMMUNOLOGY RESEARCH (2017)
The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy
Lieve Brochez et al.
EUROPEAN JOURNAL OF CANCER (2017)
The aryl hydrocarbon receptor: a multifunctional chemical sensor for host defense and homeostatic maintenance
Kaname Kawajiri et al.
EXPERIMENTAL ANIMALS (2017)
IDO1: An important immunotherapy target in cancer treatment
Fangxuan Li et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2017)
Combinatorial antitumor effects of indoleamine 2,3-dioxygenase inhibitor NLG919 and paclitaxel in a murine B16-F10 melanoma model
Xiangjing Meng et al.
INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY (2017)
Discovery of a Novel and Selective Indoleamine 2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-Fluoro-1H-indo1-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and Its Characterization as a Potential Clinical Candidate
Stefano Crosignani et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Kynurenine pathway metabolites and enzymes involved in redox reactions
D. Gonzalez Esquivel et al.
NEUROPHARMACOLOGY (2017)
Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors activate the aryl hydrocarbon receptor
Benjamin J. Moyer et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2017)
Blockade of IDO-kynurenine-AhR metabolic circuitry abrogates IFN-γ-induced immunologic dormancy of tumor-repopulating cells
Yuying Liu et al.
NATURE COMMUNICATIONS (2017)
The IDO inhibitor 1-methyl tryptophan activates the aryl hydrocarbon receptor response in mesenchymal stromal cells
Holly C. Lewis et al.
ONCOTARGET (2017)
Discovery of IDO1 Inhibitors: From Bench to Bedside
George C. Prendergast et al.
CANCER RESEARCH (2017)
BMS-986205, an optimized indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, is well tolerated with potent pharmacodynamic (PD) activity, alone and in combination with nivolumab (nivo) in advanced cancers in a phase 1/2a trial
Lillian L. Siu et al.
CANCER RESEARCH (2017)
Erianin inhibits indoleamine 2, 3-dioxygenase - induced tumor angiogenesis
Chang Su et al.
BIOMEDICINE & PHARMACOTHERAPY (2017)
Kynurenine Pathway of Tryptophan Metabolism: Regulatory and Functional Aspects
Abdulla A-B Badawy
INTERNATIONAL JOURNAL OF TRYPTOPHAN RESEARCH (2017)
1,2,3-Triazoles as inhibitors of indoleamine 2,3-dioxygenase 2 (IDO2)
Ute F. Rohrig et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2016)
Mesenchymal Inflammation Drives Genotoxic Stress in Hematopoietic Stem Cells and Predicts Disease Evolution in Human Pre-leukemia
Noemi A. Zambetti et al.
CELL STEM CELL (2016)
Establishment of a human indoleamine 2, 3-dioxygenase 2 (hIDO2) bioassay system and discovery of tryptanthrin derivatives as potent hIDO2 inhibitors
Juanjuan Li et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model
Mitsuto Hanihara et al.
JOURNAL OF NEUROSURGERY (2016)
Therapeutic targeting of inflammation and tryptophan metabolism in colon and gastrointestinal cancer
Srikanth Santhanam et al.
TRANSLATIONAL RESEARCH (2016)
IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance
David H. Munn et al.
TRENDS IN IMMUNOLOGY (2016)
Inhibiting tryptophan metabolism enhances interferon therapy in kidney cancer
Josephine F. Trott et al.
ONCOTARGET (2016)
Tryptophan Metabolism in Rat Liver After Administration of Tryptophan, Kynurenine Metabolites, and Kynureninase Inhibitors
Abdulla A. -B. Badawy et al.
INTERNATIONAL JOURNAL OF TRYPTOPHAN RESEARCH (2016)
Depletion of kynurenine using an engineered therapeutic enzyme potently inhibits cancer immune checkpoints both as a monotherapy and in combination with anti-PD-1
Everett Stone et al.
CANCER RESEARCH (2015)
Inhibition of indoleamine 2,3-dioxygenase 1 expression alters immune response in colon tumor microenvironment in mice
Manabu Takamatsu et al.
CANCER SCIENCE (2015)
The inflammatory microenvironment in MDS
Lili Yang et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2015)
Tryptophan-kynurenine pathway is dysregulated in inflammation, and immune activation
Qiongxin Wang et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2015)
Effects of indoleamine 2,3-dioxygenase inhibitor in non-Hodgkin lymphoma model mice
Nobuhiko Nakamura et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2015)
Systemic immune changes associated with adjuvant interferon-α2b-therapy in stage III melanoma patients: failure at the effector phase?
Ines Chevolet et al.
MELANOMA RESEARCH (2015)
IDO-GCN2 and autophagy in inflammation
Tracy L. McGaha
ONCOTARGET (2015)
Cancer immunotherapy by targeting IDO1/TDO and their downstream effectors
Michael Platten et al.
FRONTIERS IN IMMUNOLOGY (2015)
A phase 1b/2 study of the combination of the IDO pathway inhibitor indoximod and temozolomide for adult patients with temozolomide-refractory primary malignant brain tumors: Safety analysis and preliminary efficacy of the phase 1b component.
Howard Colman et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Pellagra and Alcoholism: A Biochemical Perspective
Abdulla A-B Badawy
ALCOHOL AND ALCOHOLISM (2014)
Human indoleamine 2,3-dioxygenase-2 has substrate specificity and inhibition characteristics distinct from those of indoleamine 2,3-dioxygenase-1
Georgios Pantouris et al.
AMINO ACIDS (2014)
Antitumour agents as inhibitors of tryptophan 2,3-dioxygenase
Georgios Pantouris et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2014)
Dual Effects of Indoleamine 2,3-Dioxygenase Inhibitors on the Therapeutic Effects of Cyclophosphamide and Cycloplatam on Ehrlich Ascites Tumor in Mice
L. A. Bogdanova et al.
BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE (2014)
Abstract 491: NLG919, a novel indoleamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy.
Mario R. Mautino et al.
CANCER RESEARCH (2014)
Interferon (IFN)-γ-mediated inflammation and the kynurenine pathway in relation to bone mineral density: the Hordaland Health Study
E. M. Apalset et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2014)
Aryl hydrocarbon receptor control of a disease tolerance defence pathway
Alban Bessede et al.
NATURE (2014)
Kynurenines with Neuroactive and Redox Properties: Relevance to Aging and Brain Diseases
Jazmin Reyes Ocampo et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2014)
Fludarabine Downregulates Indoleamine 2,3-Dioxygenase in Tumors via a Proteasome-Mediated Degradation Mechanism
Laila-Aicha Hanafi et al.
PLOS ONE (2014)
Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR
Ulrike M. Litzenburger et al.
ONCOTARGET (2014)
A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors
Hatem H. Soliman et al.
ONCOTARGET (2014)
Treg Cell Function in Rheumatoid Arthritis Is Compromised by CTLA-4 Promoter Methylation Resulting in a Failure to Activate the Indoleamine 2,3-Dioxygenase Pathway
Adam P. Cribbs et al.
ARTHRITIS & RHEUMATOLOGY (2014)
Aryl hydrocarbon receptor and kynurenine: recent advances in autoimmune disease research
Nam Trung Nguyen et al.
FRONTIERS IN IMMUNOLOGY (2014)
The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma
Minghui Li et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
Cancer/stroma interplay via cyclooxygenase-2 and indoleamine 2,3-dioxygenase promotes breast cancer progression
Jing-Yi Chen et al.
BREAST CANCER RESEARCH (2014)
A phase I/II study of the combination of indoximod and temozolomide for adult patients with temozolomide-refractory primary malignant brain tumors
Yousef Zakharia et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Resveratrol suppresses tumor progression via the regulation of indoleamine 2,3-dioxygenase
Kyung Tae Noh et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2013)
Tryptamine and dimethyltryptamine inhibit indoleamine 2,3 dioxygenase and increase the tumor-reactive effect of peripheral blood mononuclear cells
Melissa Cavalheiro Tourino et al.
CELL BIOCHEMISTRY AND FUNCTION (2013)
IDO1 Metabolites Activate β-catenin Signaling to Promote Cancer Cell Proliferation and Colon Tumorigenesis in Mice
Ameet I. Thaker et al.
GASTROENTEROLOGY (2013)
Silencing IDO in dendritic cells: A novel approach to enhance cancer immunotherapy in a murine breast cancer model
Xiufen Zheng et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
Rikke B. Holmgaard et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Bortezomib and SAHA Synergistically Induce ROS-Driven Caspase-Dependent Apoptosis of Nasopharyngeal Carcinoma and Block Replication of Epstein-Barr Virus
Kwai Fung Hui et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Metabolites of tryptophan catabolism are elevated in sera of patients with myelodysplastic syndromes and inhibit hematopoietic progenitor amplification
Celine Berthon et al.
LEUKEMIA RESEARCH (2013)
Cyclooxygenase-2 (COX-2) Inhibition Constrains Indoleamine 2,3-Dioxygenase 1 (IDO1) Activity in Acute Myeloid Leukaemia Cells
Maria Grazia Iachininoto et al.
MOLECULES (2013)
SAHA down-regulates the expression of indoleamine 2,3-dioxygenase via inhibition of the JAK/STAT1 signaling pathway in gallbladder carcinoma cells
Peng Zhang et al.
ONCOLOGY REPORTS (2013)
Induction and Role of Indoleamine 2,3 Dioxygenase in Mouse Models of Influenza A Virus Infection
Lei Huang et al.
PLOS ONE (2013)
Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer
Ben C. Creelan et al.
ONCOIMMUNOLOGY (2013)
The Tumor-Selective Cytotoxic Agent β-Lapachone is a Potent Inhibitor of IDO1
Hollie E. Flick et al.
INTERNATIONAL JOURNAL OF TRYPTOPHAN RESEARCH (2013)
Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2
Supun M. Bakmiwewa et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2012)
Clinicopathological significance of indoleamine 2,3-dioxygenase 1 expression in colorectal cancer
L. Ferdinande et al.
BRITISH JOURNAL OF CANCER (2012)
The Kynurenine Pathway in Brain Tumor Pathogenesis
Seray Adams et al.
CANCER RESEARCH (2012)
Influence of chemotherapy on nitric oxide synthase, indole-amine-2,3-dioxygenase and CD124 expression in granulocytes and monocytes of non-small cell lung cancer
Sung Hoon Sim et al.
CANCER SCIENCE (2012)
Suppression of azoxymethane-induced colonic preneoplastic lesions in rats by 1-methyltryptophan, an inhibitor of indoleamine 2,3-dioxygenase
Kengo Ogawa et al.
CANCER SCIENCE (2012)
Targeting the Interleukin-6/Jak/Stat Pathway in Human Malignancies
Pasquale Sansone et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Expansion of Effector Memory Regulatory T Cells Represents a Novel Prognostic Factor in Lower Risk Myelodysplastic Syndrome
Adam W. Mailloux et al.
JOURNAL OF IMMUNOLOGY (2012)
Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase
Luc Pilotte et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
(-)-Epigallocatechin gallate inhibits the expression of indoleamine 2,3-dioxygenase in human colorectal cancer cells
Kengo Ogawa et al.
ONCOLOGY LETTERS (2012)
IDO inhibits a tryptophan sufficiency signal that stimulates mTOR A novel IDO effector pathway targeted by D-1-methyl-tryptophan
Richard Metz et al.
ONCOIMMUNOLOGY (2012)
Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP
Soranobu Ninomiya et al.
ANNALS OF HEMATOLOGY (2011)
Molecular Basis for the Substrate Stereoselectivity in Tryptophan Dioxygenase
Luciana Capece et al.
BIOCHEMISTRY (2011)
CANCER Why tumours eat tryptophan
George C. Prendergast
NATURE (2011)
Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells
Maria T. Pallotta et al.
NATURE IMMUNOLOGY (2011)
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
Vinod P. Balachandran et al.
NATURE MEDICINE (2011)
Evaluation of indoleamine 2,3-dioxygenase expression and kynurenine pathway metabolites levels in serum samples of diabetic retinopathy patients
Praveen Kumar Munipally et al.
ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY (2011)
3-Hydroxykynurenine Suppresses CD4+ T-Cell Proliferation, Induces T-Regulatory-Cell Development, and Prolongs Corneal Allograft Survival
Sarah S. Zaher et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2011)
Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity
Xiangdong Liu et al.
BLOOD (2010)
Acyclovir inhibition of IDO to decrease Tregs as a glioblastoma treatment adjunct
Johan Soderlund et al.
JOURNAL OF NEUROINFLAMMATION (2010)
The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27
Lionel Apetoh et al.
NATURE IMMUNOLOGY (2010)
The Role of Tryptophan Catabolism along the Kynurenine Pathway in Acute Ischemic Stroke
Raf Brouns et al.
NEUROCHEMICAL RESEARCH (2010)
Oxidative stress damage and oxidative stress responses in the choroid plexus in Alzheimer's disease
Ester Perez-Gracia et al.
ACTA NEUROPATHOLOGICA (2009)
Functional Interaction of Plasmacytoid Dendritic Cells with Multiple Myeloma Cells: A Therapeutic Target
Dharminder Chauhan et al.
CANCER CELL (2009)
Advancements in the molecular pathogenesis of myelodysplastic syndrome
Pearlie K. Epling-Burnette et al.
CURRENT OPINION IN HEMATOLOGY (2009)
Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway
Helen J. Ball et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2009)
Dominant Role of Antigen Dose in CD4+Foxp3+ Regulatory T Cell Induction and Expansion
Michael S. Turner et al.
JOURNAL OF IMMUNOLOGY (2009)
Cutting Edge: The Foxp3 Target miR-155 Contributes to the Development of Regulatory T Cells
Susan Kohlhaas et al.
JOURNAL OF IMMUNOLOGY (2009)
On the relationship between the two branches of the kynurenine pathway in the rat brain in vivo
Laura Amori et al.
JOURNAL OF NEUROCHEMISTRY (2009)
Indoleamine 2,3-dioxygenase as a new target for malignant glioma therapy Laboratory investigation
Takeshi Miyazaki et al.
JOURNAL OF NEUROSURGERY (2009)
The paradoxical patterns of expression of indoleamine 2,3-dioxygenase in colon cancer
Yan-Fang Gao et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2009)
STATs in cancer inflammation and immunity: a leading role for STAT3
Hua Yu et al.
NATURE REVIEWS CANCER (2009)
The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation
Wei Chen et al.
JOURNAL OF IMMUNOLOGY (2008)
Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells
Stefan Lob et al.
BLOOD (2008)
Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses
De-Yan Hou et al.
CANCER RESEARCH (2007)
Molecules in focus: Indoleamine 2,3-dioxygenase
Nicholas J. C. King et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2007)
Kynurenine pathway metabolism in patients with osteoporosis after 2 years of drug treatment
Caroline M. Forrest et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2006)
Reinstalling antitumor immunity by inhibiting tumor-derived immunosuppressive molecule IDO through RNA interference
Xiufen Zheng et al.
JOURNAL OF IMMUNOLOGY (2006)
Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: Role of IDO
Gargi D Basu et al.
JOURNAL OF IMMUNOLOGY (2006)
Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer:: Effect on tumor-infiltrating T cells
G Brandacher et al.
CLINICAL CANCER RESEARCH (2006)
Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells
A Okamoto et al.
CLINICAL CANCER RESEARCH (2005)
GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase
DH Munn et al.
IMMUNITY (2005)
Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy
AJ Muller et al.
NATURE MEDICINE (2005)
The role of IFN-gamma and TNF-alpha-responsive regulatory elements in the synergistic induction of indoleamine dioxygenase
CM Robinson et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2005)
In vivo and in vitro evaluation of erianin, a novel anti-anglogenic agent
YQ Gong et al.
EUROPEAN JOURNAL OF CANCER (2004)
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase
C Uyttenhove et al.
NATURE MEDICINE (2003)
Cutting edge: Induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion
AL Mellor et al.
JOURNAL OF IMMUNOLOGY (2003)
Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division
GK Lee et al.
IMMUNOLOGY (2002)
Manipulation of brain kynurenines: Glial targets, neuronal effects, and clinical opportunities
R Schwarcz et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
T cell apoptosis by tryptophan catabolism
I Fallarino et al.
CELL DEATH AND DIFFERENTIATION (2002)
Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase
DH Munn et al.
SCIENCE (2002)
Increased levels of 3-hydroxykynurenine in different brain regions of rats with chronic renal insufficiency
J Topczewska-Bruns et al.
BRAIN RESEARCH BULLETIN (2002)
Purification and biochemical characterization of some of the properties of recombinant human kynureninase
HA Walsh et al.
EUROPEAN JOURNAL OF BIOCHEMISTRY (2002)
Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation
P Hwu et al.
JOURNAL OF IMMUNOLOGY (2000)
Human placental indoleamine 2,3-dioxygenase: cellular localization and characterization of an enzyme preventing fetal rejection
Y Kudo et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2000)
Share Paper
